Distribution of recurrence time intervals after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization

Can J Ophthalmol. 2021 Apr;56(2):137-138. doi: 10.1016/j.jcjo.2020.08.004. Epub 2020 Sep 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Choroidal Neovascularization* / diagnosis
  • Choroidal Neovascularization* / drug therapy
  • Choroidal Neovascularization* / etiology
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Myopia, Degenerative* / complications
  • Myopia, Degenerative* / diagnosis
  • Myopia, Degenerative* / drug therapy
  • Ranibizumab / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Ranibizumab